$3.00
At close: Apr 16 EDT
$3.00
0.000.00%
Pre-Market: 4:00 PM EDT
Comments
Loading...
Atea Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:AVIR | Benzinga
Atea Pharmaceuticals Inc has a consensus price target of $6 based on the ratings of 3 analysts. The high is $6 issued by Morgan Stanley on April 11, 2025. The low is $6 issued by Morgan Stanley on April 11, 2025. The 3 most-recent analyst ratings were released by Morgan Stanley, Morgan Stanley, and JP Morgan on April 11, 2025, August 13, 2024, and March 16, 2023, respectively. With an average price target of $6.96 between Morgan Stanley, Morgan Stanley, and JP Morgan, there's an implied 132.00% upside for Atea Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
SVB Leerink
1calculated from analyst ratings
Analyst Ratings for Atea Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/11/2025 | Buy Now | 100% | Morgan Stanley | Matthew Harrison62% | $6.2 → $6 | Maintains | Equal-Weight | Get Alert |
| 08/13/2024 | Buy Now | 129.33% | Morgan Stanley | Matthew Harrison62% | $2 → $6.88 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 08/10/2023 | Buy Now | — | JP Morgan | Eric Joseph43% | — | Downgrade | Neutral → Underweight | Get Alert |
| 03/16/2023 | Buy Now | 166.67% | JP Morgan | Eric Joseph43% | $12 → $8 | Maintains | Neutral | Get Alert |
| 01/27/2023 | Buy Now | 100% | SVB Leerink | Roanna Ruiz34% | $8 → $6 | Maintains | Market Perform | Get Alert |
| 01/24/2023 | Buy Now | 33.33% | Morgan Stanley | Matthew Harrison62% | $7 → $4 | Maintains | Underweight | Get Alert |
| 08/15/2022 | Buy Now | 133.33% | Morgan Stanley | Matthew Harrison62% | $6 → $7 | Maintains | Underweight | Get Alert |
FAQ
What is the target price for Atea Pharmaceuticals (AVIR) stock?
The latest price target for Atea Pharmaceuticals (NASDAQ:AVIR) was reported by Morgan Stanley on April 11, 2025. The analyst firm set a price target for $6.00 expecting AVIR to rise to within 12 months (a possible 100.00% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Atea Pharmaceuticals (AVIR)?
The latest analyst rating for Atea Pharmaceuticals (NASDAQ:AVIR) was provided by Morgan Stanley, and Atea Pharmaceuticals maintained their equal-weight rating.
When was the last upgrade for Atea Pharmaceuticals (AVIR)?
The last upgrade for Atea Pharmaceuticals Inc happened on August 13, 2024 when Morgan Stanley raised their price target to $6.88. Morgan Stanley previously had an underweight for Atea Pharmaceuticals Inc.
When was the last downgrade for Atea Pharmaceuticals (AVIR)?
The last downgrade for Atea Pharmaceuticals Inc happened on August 10, 2023 when JP Morgan changed their price target from N/A to N/A for Atea Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Atea Pharmaceuticals (AVIR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atea Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atea Pharmaceuticals was filed on April 11, 2025 so you should expect the next rating to be made available sometime around April 11, 2026.
Is the Analyst Rating Atea Pharmaceuticals (AVIR) correct?
While ratings are subjective and will change, the latest Atea Pharmaceuticals (AVIR) rating was a maintained with a price target of $6.20 to $6.00. The current price Atea Pharmaceuticals (AVIR) is trading at is $3.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
